Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Semaglutide slows blood protein signature linked to future dementia risk

10

Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

Heavy rainfall and flooding raise infectious disease risks across Europe

10

Aug 2026

Heavy rainfall and flooding raise infectious disease risks across Europe

A rapid review of 14 studies found that heavy rainfall and flooding were associated with outbreaks and increased incidence of several infectious diseases across Europe, particularly campylobacteriosis and leptospirosis. The authors highlighted major evidence gaps and called for stronger One Health surveillance, public health communication, sanitation, and flood-response planning.

H5N1 infections remain rare among workers exposed to infected birds

10

Aug 2026

H5N1 infections remain rare among workers exposed to infected birds

A two-year cohort study of 428 people exposed to H5N1-infected birds in England found fewer than 1% met criteria for infection, with no severe disease or secondary human transmission. The findings support continued PPE use, biosecurity, and targeted surveillance while highlighting challenges around occupational exposure, mucosal contamination, and pandemic preparedness.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.